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ABSTRACT   Brain natriuretic peptide (BNP), as a hematological biomarker, has been widely 
used in congenital heart disease (CHD). However, its sensitivity and specificity vary depending 
on age and pathological condition. In the present study, we assessed whether reactive oxygen 
metabolites (ROMs) and biological antioxidant potential (BAP), as oxidative stress indicators, 
could be new biomarkers in CHD.
   Forty-two patients diagnosed with CHD were enrolled in this study. The levels of ROMs, 
BAP, BNP, cardiac muscle creatinine kinase, and heart-type fatty acid-binding protein were 
measured using the findings of echocardiography. The ROM and BNP levels were significantly 
higher than the standard reference levels. The estimated Qp/Qs correlated mildly with BNP 
and ROM levels. The medication caused a significant decrease in BNP and ROM levels. The 
optimal decision, Qp/Qs greater than 1.5, estimated from receiver operator characteristic (ROC) 
curves was 371 U.CARR (58% sensitivity, 90% specificity) for ROMs, and that for BNP was 
28.4 pg/ml (97% sensitivity 45% specificity). Direct comparison of ROMs and BNP did not 
show significantly different area under the curve values.
   ROM levels can be a new biomarker for oxidative stress evaluation in children with CHD 
at almost the same sensitivity as the previous biomarkers, and an effective indicator when 
combined with other biomarkers and indicators.
 doi：10.11482/KMJ-E202046125　(Accepted on September 14, 2020)




   The frequency of congenital heart disease (CHD) 
in children is about 1%, including hemodynamic 
abnormalities caused by impaired sites in the 
developmental stage of the heart in the fetal period 
and various diseases caused thereby. Concerning the 
severity of the disease, there is a wide range from 
those that naturally heal to those that require surgical 
intervention in the early postnatal period. Precise 
and accurate medical treatment or preoperative/
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ROMs and BAP compared to previous biomarkers, 
BNP, CK-MB, and H-FABP.
MATERIALS AND METHODS
Patient Population
   We enrolled children (0-15 years) with CHD, who 
were diagnosed at the Kawasaki Medical School 
between September 2016 and March 2019. All 
patients were diagnosed using echocardiography 
by a skil led pediatr ic cardiologist .  Patient 
characteristics, blood test results, echocardiographic 
findings, and clinical course were reviewed from the 
medical records. The patients with basal diseases 
other than CHD or history of cardiac surgery 
were excluded. The procedures followed were in 
accordance with the “Declaration of Helsinki” and 
the ethical standards of the responsible institutional 
committee on human experimentation. The study 
was approved by the Kawasaki Medical School 
Hospital Institutional Ethics Review Board 
(Reference Number: 2476). The written informed 
consent was obtained from the study subjects (or 
their parents).
Measurement of Blood Parameters, and ROM and 
BAP Levels
   We performed blood tests in our clinic as needed 
for each visit. These were performed to measure 
levels of plasma, BNP (reference value: < 18.4 pg/
ml), CK-MB, and H-FABP as previous biomarkers. 
The blood samples were stored at -80℃ until 
analysis. 
   The principle of the ROM and BAP test has been 
described previously15，16）. Levels of both ROMs 
and BAP were measured using a Free Radical 
Elective Evaluator (FREE Carrio Duo®; Wismerll 
Co Ltd, Tokyo, Japan). The ROM test was based 
on the ability of transition metals to catalyze the 
formation of free radicals trapped by alchilamine in 
the presence of peroxides. The alchilamine reacted 
to form a colored radical; the concentration was 
postoperative management influences the prognosis. 
In order to assess the medical condition in children 
with CHD, brain natriuretic peptide (BNP), a 
hematological biomarker of heart failure１）, as well 
as cardiac muscle creatinine kinase (CK-MB) and 
heart-type fatty acid-binding protein (H-FABP), 
markers of associated myocardial damage, are 
widely used. These markers reflect the volume and 
pressure overload of the ventricles and atriums 
as well as myocardial damage. However, their 
sensitivity and specificity vary depending on the age 
and pathological condition. Especially in the case 
of BNP, newborns are likely to have high values 
and many false positives and negatives due to other 
pathological conditions２，３）. Furthermore, there is a 
certain time lag at the clinical site before it reflects 
hemodynamics, and the amount of blood collected is 
about 5 ml, which is very large for low-birth-weight 
newborns and infants. Therefore, there is a need for 
the discovery of alternative new biomarkers.
   Oxidative stress occurs when there is a disruption 
in the balance between the production and 
elimination of reactive oxygen species (ROS). 
Oxidative stress is associated with various 
cardiovascular diseases, including myocardial 
infarction and hypertension in adults４－９）, and 
Kawasaki disease in children10－13）. The association 
between oxidative stress and vascular or myocardial 
disorders has been clarified; however, there is no 
report of an association between heart failure due to 
CHD in children caused by oxidative stress. On the 
other hand, reactive oxygen metabolites (ROMs) 
and biological antioxidant potential (BAP) have 
been identified as oxidative stress biomarkers with 
high reproducibility and stability14）. 
   We hypothesized that ROMs and BAP for 
oxidative stress evaluation could serve as new 
biomarkers in children with CHD. We aimed to 
investigate the correlation between the change in 
oxidative stress levels and the severity of CHD, 
further assessing the equivalence or superiority of 
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measured using spectrophotometry (505 nm). The 
results were expressed in conventional units called 
U.CARR (Carrtelli units), such that 1 U.CARR 
corresponded to 0.8 mg/l H2O2. Also, the BAP 
test was based on the ability of a colored solution, 
containing a source of ferric irons bound to a unique 
chromogenic substrate, to decolorize when ferric 
irons were reduced to ferrous iron when a reducing/
antioxidant source was added. The concentration 
was then measured using spectrophotometry (505 
nm). The standard reference levels of ROMs and 
BAP were 250 to 300 U.CARR and over 2,200 μM, 
respectively.
Evaluation of CHD
   All children underwent echocardiography using 
Aplio™ 300 (CANON Medical Systems Co Ltd, 
Tochigi, Japan), to assess the morphology, volume, 
and pressure load on the ventricles and atria. 
Measurement sites to evaluate the medical condition 
and severity varied for each disease. However, 
the standard measurement sites used were left 
ventricular end-diastolic diameter (LVEDD), left 
ventricular end-systolic diameter (LVESD), left 
ventricular ejection fraction (LVEF), left ventricular 
fractional shortening (LVFS), and right ventricular 
end-diastolic diameter (RVEDD). Each percentage 
was calculated according to standard values17）.
   The estimated ratio of the pulmonary to 
systemic blood flow (Qp/Qs) was defined by using 
2-D echocardiography18） and spectral Doppler 
measurements in patients who had intra-cardiac 
shunts. 
   Qp = right ventricular outflow tract (RVOT) 
subvalvular velocity time integral (VTI) × π × 
(RVOT/2)2
   Qs = left ventricular outflow tract (LVOT) 
subvalvular velocity time integral (VTI) × π × 
(LVOT/2)2
   The estimated ratio of the right ventricular 
pressure (RVP) to left ventricular pressure (LVP) 
was defined by the interventricular septal (IVS) 
curvature index from the short-axis view using 2-D 
echocardiography measurements in patients who 
had pulmonary hypertension.
Data Collection
   Collected data included patient demographics, 
d i a g n o s i s  o f  C H D ,  b l o o d  t e s t  r e s u l t s , 
echocardiography findings, and the clinical course. 
Clinical data were collected at each visit as needed. 
All children underwent echocardiography under the 
supervision of a pediatric cardiologist. Levels of 
both ROMs and BAP were measured in triplicates, 
and the median was adopted. If there had been any 
clinical intervention, medication, or surgical repair, 
the post-intervention data were defined after the 
patient was stabilized. 
Statistical Analysis
   Continuous variables were expressed as mean, 
standard deviation, median and range depending 
on the distribution of each variable. Comparisons 
of continuous data, measured at the baseline for the 
study groups, were analyzed using the Wilcoxon 
signed-rank test. Correlation analysis was performed 
using the Spearman’s rank correlation. The 
diagnostic efficiency of biomarkers was compared 
using ROC curve analysis with a comparison of 
area under the curve (AUC). A P-value of < 0.05 
was considered significant. Statistical analyses 
were performed using the SPSS statistical software, 
version 25.0 (SPSS Inc, Chicago, Illinois, USA).
RESULTS
Patient Characteristics
   Forty-two patients (13  males), diagnosed 
with CHD, were enrolled in this study between 
September 2016 and March 2019. The median age 
was 1.3 years (range 10 days-5.2 years), and weight 
was 9.4 kg (range 2.9-17.2 kg). Most patients, 
except one, had acyanotic CHD, 16 (38%) had an 
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atrium septal defect (ASD), and 15 (36%) had a 
ventricular septal defect (VSD). During the study, 
10 (24%) were introduced to medication, 4 (10%) 
underwent surgical intervention (Table 1). 
Initial Biomarker Data and Echocardiography 
Findings
   Initial biomarker data collected at the first visit 
are summarized in Table 2. The ROM (411 ± 71 
U.CARR) and BNP (36.3 ± 80.3 pg/ml) levels were 
significantly higher than the standard reference 
levels. Alternatively, the BAP, CK-MB, and 
H-FABP levels were almost within the normal 
range. Initial findings of echocardiography are 
summarized in Table 3. All patients had LVEF over 
70%. All diagnoses, except valvular pulmonary 
stenosis (PS), were evaluated using mean estimated 
Qp/Qs over 1.5. 
Table 1. Demographics of all patients included in the study.
All patients
(n = 42)
Age (median) 1.3 years (10 days - 5.2 years)
Males 13 (30%)










　Introduced Medication 10 (24%)
　　Diuretics 10
　Underwent Surgical repair 4 (10%)
Follow-up 
　Times (median) 3 (1-13)
　Duration (median : days) 553 (1-1029)
VSD, ventricular septal defect; ASD, atrium septal defect; PDA, 
patent ductus arteriosus; PS, pulmonary stenosis; CAVSD, 
complete atrium ventricular septal defect.











Total (mean± SD) 411 ± 71 2604 ± 192 36.3 ± 80.3 29.3 ± 19.0 5.0 ± 4.0
Diagnosis
　ASD 427 ± 63 2632 ± 184 17.2 ± 17.2 23.5 ± 6.8 3.7 ± 1.9
(+PS) 417 ± 71 2739 ± 142 12.9 ± 12.6 26.5 ± 3.2 5.3 ± 2.0
　VSD 386 ± 80 2537 ± 229 46.3 ± 94.3 30.2 ± 8.5 5.4 ± 6.2
(+ASD) 419 2459 341.9 17 2.3
　Valvular PS 401 ± 52 2648 ± 128 16.1 ± 8.1 30.3 ± 5.1 6.1 ± 2.6
　PDA 431 ± 78 2618 ± 135 27.3 ± 26.8 22.3 ± 4.1 7.4 ± 1.6
　CAVSD 582 2587 396 15 2.3
ROMs, reactive oxygen metabolites; BAP, biological antioxidant potential, BNP, brain natriuretic peptide; CK-MB, cardiac muscle 
creatinine kinase; H-FABP, heart-type fatty acid-binding protein; SD, standard deviation; VSD, ventricular septal defect; ASD, atrium 
septal defect; PDA, patent ductus arteriosus; PS, pulmonary stenosis; CAVSD, complete atrium ventricular septal defect.












　ASD 101 ± 5.4 71 ± 5.3 193 ± 41.9 1.63 ± 0.45 0.35 ± 0.08
(+PS) 97 ± 2.2 72 ± 7.5 212 ± 29.1 1.75 ± 0.05 0.44 ± 0.04
　VSD 137 ± 17.1 71 ± 4.3 124 ± 20.9 1.58 ± 0.75 0.37 ± 0.13
(+ASD) 158 ± 17.1 71 ± 3.3 161 ± 5.3 2.52 ± 1.19 0.57 ± 0.15
　Valvular PS 104 ± 4.2 74 ± 5.8 110 ± 2.2 1 0.36 ± 0.04
　PDA 136 ± 13.8 72 ± 4.5 105 ± 8.7 1.68 ± 0.77 0.41 ± 0.19
　CAVSD 170 79 250 3.8 0.80
LVEDD, left ventricle end-diastolic diameter; RVEDD, right ventricle end-diastolic diameter; Qp/Qs, pulmonary to systemic blood 
flow ratio; RVP, right ventricle pressure; LVP, left ventricle pressure; VSD, ventricular septal defect; ASD, atrium septal defect; PDA, 
patent ductus arteriosus; PS, pulmonary stenosis; CAVSD, complete atrium ventricular septal defect.
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Correlation Between Biomarkers and the Severity of 
Load in Echocardiography
   The  sca t t e r  p lo t s  show the  cor re la t ion 
between biomarkers and estimated Qp/Qs in 
echocardiography (Fig. 1). The estimated Qp/Qs 
was correlated mildly with BNP (r = 0.372, p < 0.01) 
and ROM (r = 0.304, p < 0.01) levels, whereas, it 
was not correlated with BAP (r = 0.119, p = 0.156) 
levels.
Change in Biomarkers in Clinical Interventions
   Medication caused a significant decrease in BNP 
levels from 69.2 (median: 28.9-396.1) to 43.2 pg/
ml (median: 14.7-242) (p < 0.01), and also in ROM 
levels from 424 (median: 350-562) to 360 U.CARR 
(median: 282-436) (p < 0.01). Surgical repair caused 
a significant decrease in BNP levels from 106.4 
(median: 48.5-242) to 13.1 pg/ml (median: 8.1-18) 
(p < 0.01). There was no significant change in ROM 
levels from 443 (median: 424-562) to 319 U.CARR 
(median: 269-371), but it tended to decrease. In 
contrast, there were no significant changes in BAP 
levels after both clinical interventions (Fig. 2).
Diagnostic Efficiency of BNP and ROMs
   One of the surgical indications in left-right shunt 
disease was defined as Qp/Qs greater than 1.5 in 
echocardiography findings. The optimal decision 
threshold, estimated from ROC curves was 371 
U.CARR (58% sensitivity, 90% specificity) for 
ROMs and 28.4 pg/ml (97% sensitivity 45% 
specificity) for BNP. Direct comparison of 
ROMs and BNP gave AUCs of 0.804 (95% CI: 
0.711-0.896) and 0.700 (95% CI: 0.579-0.820), 
respectively. The difference between AUC for 
ROMs and BNP was not significant (p = 0.205). 
The ROC curves are shown in Fig. 3.
DISCUSSION
   This study examined the ROMs and BAP levels 
for oxidative stress evaluation in children with CHD 
and explored their potential as new biomarkers. 
We clarified that the levels of ROMs were almost 
equivalent to those of BNPs. 
   In this study, all patients except one had acyanotic 
CHD, among which 86% had left-right shunt 
disease. Initial findings of echocardiography 
suggested volume overload in ASD, VSD, PDA, 
and CAVSD, also pressure overload in valvular 
PS as the primary etiologies. ROM levels are high 
even though ASD and valvular PS are generally less 
likely to raise BNP levels compared to the degree 
of cardiac load19）. In VSD, PDA, and CAVSD, the 
ROM and BNP levels were high due to volume 
overload, and in valvular PS, they were high due to 




Fig. 1. Correlation between biomarkers and Qp/Qs obtained using the Pearson’s correlation analysis. BNP, brain natriuretic 
peptide; ROMs, reactive oxygen metabolites; BAP, biological antioxidant potential.


























































Fig. 2. Change in biomarkers before and after clinical interventions. 
BNP, brain natriuretic peptide; ROMs, reactive oxygen metabolites; BAP, biological antioxidant potential.
Fig. 3. Test results for the difference in AUC value between BNP and ROMs. 
BNP, brain natriuretic peptide; ROMs, reactive oxygen metabolites; AUC, area 
under the curve.
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normal range in all patients. Several studies have 
reported that myocardial injury is associated with 
oxidative stress20－22）. However, in this study, ROM 
levels were high, even though the echocardiography 
showed good cardiac function, and CK-MB and 
H-FABP levels were almost within the normal 
range. This suggested that a high level of ROMs was 
due to volume and pressure overload. Pirinccioglu, 
A.G. et al. (2012) have confirmed that the levels of 
inflammatory cytokines increase in CHD23）. They 
may be associated with the level of oxidative stress. 
   We determined the degree of force to predict the 
severity of the volume load using the estimated Qp/
Qs and various echocardiography measurements 
in left-right shunt disease. BNP and ROM levels 
showed equivalent and mild correlation with these 
measurements; however, BAP was not correlated 
with them. We presumed that the inaccuracy in 
the estimated Qp/Qs using echocardiography 
and not cardiac catheterization resulted in a 
milder correlation for BNP (r = 0.372) than what 
was expected. Initially, all patients should have 
undergone cardiac catheterization to calculate 
accurate Qp/Qs;  however,  we avoided this 
because not all patients were surgical candidates. 
Furthermore, ROMs tended to have more variation 
than those exhibited by BNP, suggesting that it had 
a relatively small individual difference. 
   Further, regarding the change in biomarker levels 
via clinical interventions, both BNP and ROMs 
significantly decreased with medication. Since 
all the medications were diuretics, we assumed 
that the reduction of cardiac overload affected 
their decrease. There were few cases of surgical 
intervention with cardiopulmonary bypass (CPB), 
but this also decreased BNP and ROM levels. There 
was no significant increase or decrease in BAP 
levels. Caputo, M. et al. (2014) have reported that 
CPB leads to reoxygenation injury with significant 
myocardium damage and triggers a systemic 
inflammatory response24）; therefore, we expected 
a temporary increase in ROMs25）. However, the 
hemodynamics were radically improved and 
stabilized compared to those observed immediately 
after surgical repair, and it had a more substantial 
impact; therefore, ROM levels were significantly 
decreased.
   We also compared the diagnostic efficiency of 
BNP and ROMs as biomarkers with the Qp/Qs ratio, 
which have been efficiently used for considering 
surgical indication; as a result, no significant 
difference was observed. However, the specificity 
of ROMs was relatively higher than that of BNP; 
therefore, it may help to determine the indication for 
surgical intervention. 
   Our data suggest that ROMs can be a new 
biomarker for oxidative stress evaluation in children 
with CHD, as their efficacy was almost equivalent 
to, but not superior to, previous biomarkers. ROMs 
are expected to be widely used in clinical settings 
because the blood volume needed is small, and 
measurement can be easily performed in a short 
time. However, since there are some individual 
variations, we presumed that it might be better to 
evaluate changes in the values in order to assess 
the transition of the medical condition of the same 
patient, rather than using it for diagnosis in terms of 
the degree of the cardiac load. Additionally, it may 
be possible to predict the surgical indication using 
the cut-off value while successfully combining with 
BNP. Further studies with long-term follow-up are 
required to verify the efficacy of ROM levels in 
assessing the medical condition of the same patient 
and their impact on CHD management strategy. 
Futhermore, the usefulness in adult congenital heart 
disease and pediatric arrhythmia may be considered 
in the future.
   This study has several limitations. This is a single-
institute research comprising a limited number of 
children with CHD. There were some variations in 
the initial levels of ROMs and BAP. The estimated 
Qp/Qs were not evaluated by catheterization 
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because some cases evidently did not require 
surgical interventions. Finally, follow-up data were 
collected for < 2 years, only three times, which 
might have introduced a bias into the results.
   Nevertheless, these initial results show that ROM 
levels can be a new biomarker for oxidation stress 
evaluation in children with CHD at almost the same 
sensitivity as the previous biomarkers. However, 
there are some individual variations, and further 
long-term follow-up is required to determine their 
efficacy and impact on CHD management.
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